CROSSJECT Reports Its First-Half 2026 Results and Presents a Significantly Strengthened Financial Structure
Filed with Euronext · · 7 pages · French
Summary by 6ix AI
The company reported a major increase in equity and a substantial reduction in net financial debt during this period. Despite a decrease in revenue compared to the previous year, operational expenses remained stable, reflecting ongoing development activities. The report also notes advancements in regulatory and industrial preparations for ZEPIZURE®, a treatment for severe epilepsy crises.
Written in English by 6ix AI from the company’s French-language filing. How 6ix writes summaries
Trésorerie de 12,3 M€ au 30 juin 2026, multipliée par 2,4 par rapport au 31 décembre 2025 (5,1 M€), après l’augmentation de capital de 15 M€ réalisée en mai. Capitaux propres redevenus positifs à 3,0 M€ (−4,9 M€ au 31 décembre 2025) et endettement financier net ajusté réduit de plus de moitié, à 7,8 M€ (17,4 M€). Facturation BARDA de 2,5 M€ (6,6 M€ au S1 2025), le S1 2025 ayant concentré la campag
Story so far
Earlier from Crossject
- CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée
- CROSSJECT and BARDA align ZEPIZURE®’s Pediatric development plan with FDA including funding through 2030
- Information relative au nombre total de droits de vote et d'actions composant le capital social
- CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million
- CROSSJECT appoints Lionel Seltz as Chief Financial Officer
Later from Crossject
All Crossject news releasesFollow Crossject into a list and get an email when it puts out news.
Follow Crossject